The Role of Bioactive Compounds in the Prevention of Rheumatoid Arthritis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (20 February 2025) | Viewed by 11138
Special Issue Editor
2. CICS/UBI, Universidade da Beira Interior, Covilhã, Portugal
Interests: bioactive compounds; phytochemicals; natural products as health promoters; chronic diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Rheumatoid arthritis (RA) is a multifactorial disease that involves both genetic predisposition and environmental components. In 2019, there were 18 million RA patients worldwide. Aproximately 70% of RA patients are women, and 55% are older than 55 years. Thirteen million people with rheumatoid arthritis experience severity levels (moderate or severe) that could benefit from rehabilitation. RA is characterized by chronic inflammation of the synovial membrane that lines the joints, damage to the cartilage, and erosion of the bone. Bioactive compounds are dietary ingredients that provide beneficial health effects to functional foods and nutraceuticals. These compounds exhibit antioxidant and anti-inflammatory activities, as well as additional preventative properties. Bioactive compounds found in natural food products can control arthritic inflammation through multiple pathways, for example the inhibition of effector molecules (e.g., cytokines and chemokines), induction of anti-inflammatory mediators (e.g., IL-4, IL-10), regulation of the Th17/Treg balance, and modulation of osteo-immune cross-talk.
Dr. Luís Manuel Lopes Rodrigues Da Silva
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bioactive compounds
- functional foods
- nutraceuticals
- rheumatoid arthritis
- anti-inflamatory activity
- anti-inflammatory mediators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
